Drug intelligence / Profile preview

FE 999324

Development stage: Discontinued
Lead developer: Ferring Pharmaceuticals
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

FE 999324 is an investigational **oral microbiota capsule** being developed by Ferring as a microbiome therapeutic for **ulcerative colitis**. In the registered Phase 1 proof-of-concept study NCT06260267, FE 999324 was described as a **microbiota capsule** and evaluated against placebo in adults with mild to moderate ulcerative colitis. Its intended mechanism appears to be **modulation of the gut microbial ecosystem** rather than engagement of a single defined molecular target, with the therapeutic hypothesis that restoring or reshaping intestinal microbiota may reduce mucosal inflammation in ulcerative colitis. Publicly verifiable information is limited, and the identified trial was later **withdrawn for strategic reasons rather than safety concerns**.

Other names: microbiota capsule

Beyond the preview

Go deeper on FE 999324.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FE 999324.

Explore the full profile